BiomarkersHumans
Classification performance of the Lumipulse ® G pTau 217 Plasma assay and Lumipulse ® G pTau 217/β‐Amyloid 1‐42 Plasma Ratio in a preclinical cohort
AAIC 2025 Abstract
Abstract
Background: The Lumipulse ® G pTau217 assay is among the highest performing plasma assays available for detecting amyloid pathology. Recently, Fujirebio has submitted the Lumipulse ® G pTau 217/β‐Amyloid 1‐42 Plasma Ratio to the FDA.
